Equity Research Health Information Services

Should You Buy NRC Health Stock in 2026?

By CirclFi Research Team · · Updated · 9/13 models active

According to the CirclFi Deep Alpha Valuation Engine, NRC Health (NRC) carries a solid Quality of Company rating of 7.0/10. Trading at $21.96, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 2 of 9 CirclFi valuation models project upside for NRC Health (NRC) at $21.96 — the model consensus leans bearish, with a Quality Score of 7.0/10 and Value-Trap risk of 34/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 9 models suggest overvaluation — majority bearish
  • Quality Score: 7.0/10 — Strong — above-average quality
  • Value Trap Risk: 34/100 — Low — manageable risk
  • Fair Value Range: $2.02 – $35.47 (1660% spread)

Bullish Models

2 / 9

Bearish Models

7 / 9

Quality Score

7.0 /10

Strong — above-average quality

Value Trap Risk

34 /100
Low

Low — manageable risk

Model Consensus

9 /13
Active Models

Avg. confidence: 52%

What Is the Investment Case for NRC Health (NRC) in 2026?

What Is the Bull Case vs the Bear Case for NRC Health (NRC)?

Bull case versus bear case for NRC Health (NRC) at $21.96, derived from 9 active CirclFi valuation models on 2026-09-15.
Bull case — $35.47 target (+61.5%) Bear case — $2.02 target (-90.8%)
According to the CirclFi Quality of Company (QOC) framework, NRC Health's quality score of 7.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $2.02 (-90.8%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $35.47 (+61.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens. According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +152.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does NRC Compare to Its Health Information Services Peers?

SDGR Schrödinger, Inc.
7.1
DH Definitive Healthcar
7.0
BTSG BrightSpring Health
7.2
WEAV Weave Communications
6.6
TDOC Teladoc Health, Inc.
7.3
SY So-Young Internation
6.6
SOPH SOPHiA GENETICS SA
5.9
MSPR MSP Recovery, Inc.
4.7

Valuation data pages: SDGR · DH · BTSG · WEAV · TDOC · SY · SOPH · MSPR · VASO · DOCS · HQY

See full Health Information Services rankings →

Which Other Stocks Score Like NRC on Quality?

Closest companies to NRC’s Quality of Company score of 7.0/10, across all industries.

Why Do CirclFi’s 9 Models Disagree on NRC?

Spread

1660%

Fair Value Range

$2.02 – $35.47

A 1660% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Regime Cross

$35.47 (+61.5%)

Most Bearish

EROIC

$2.02 (-90.8%)

What Are the Biggest Risks of Buying NRC Stock?

Model Disagreement

1660% spread signals high variance in projections.

Bearish Consensus

7/9 models suggest overvaluation.

Macro/Sector Risk

Health Information Services headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View NRC Data Page →

So Is NRC Health (NRC) Worth Buying in 2026?

Caution dominates our read on NRC Health at $21.96. 6 of 9 models see limited upside or outright downside, with the median fair value at $13.20 (-39.9%). Quality at 7.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. NRC Health's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About NRC Stock?

Should I buy NRC stock right now?

Based on CirclFi's multi-model analysis, 2 of 9 models see upside for NRC at $21.96. The models are divided, which means the investment case depends heavily on your assumptions about NRC Health's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in NRC Health?

Key risks include: wide model disagreement (1660% spread), signaling high uncertainty; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.

How does NRC compare to its competitors?

Among Health Information Services peers, NRC holds a Quality Score of 7.0/10. Comparable companies include SDGR (QOC 7.1), DH (QOC 7.0), BTSG (QOC 7.2). The relative ranking helps investors identify whether NRC offers better fundamental quality than alternatives in the same sector.

Is NRC a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NRC's Quality Score of 7.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy NRC at?

CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $2.02 to $35.47. At $21.96, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for NRC.

View NRC Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →